NCT04624672View on ClinicalTrials.gov

Treatment of GLP-1 for Diabetic Bariatric Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

August 17, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide (1 Mg Dose)

Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery

DRUG

Placebo

Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery

Trial Locations (1)

17822

Geisinger Medical Center, Danville

Sponsors

Lead Sponsor

Geisinger Clinic

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Geisinger Clinic

OTHER